Celldex Therapeutics vaccine might double survival in sufferers with deadly brain tumors A vaccine aimed at inducing immunity to the most common and deadly type of brain tumor may push away recurrence and a lot more than double survival in patients, according to a new study led by researchers in Duke’s Preston Robert Tisch Brain Tumor Middle. ‘This vaccine represents a very promising therapy for a malignancy that comes out of the blue and robs folks of something the majority of us take for granted – – period,’ said John Sampson, M www.malegra-plus.com/malegra-fxt-and-malegra-fxt-plus-directions-for-use.htm .D., Ph.D., a neurosurgeon at Duke and lead investigator on this study.
Cellix expands European distribution network with Tebu-bio Cellix are pleased to announce the signing of a distribution contract with tebu-bio SAS. Tebu-bio has a well-established pan-European existence, recognised by the worldwide scientific community with local offices in France, Germany, Belgium, holland, Italy, Denmark, Portugal, Spain and the united kingdom. Cellix’s selection of biochips and add-ons are now available for purchase from tebu-bio for an array of applications including investigation of platelet biology, thrombi development, the leukocyte adhesion cascade; biofilm formation and colonisation; and oncology studies. These biochips are compatible with regular syringe pumps from Harvard Apparatus, World Accuracy Instruments, KD Scientific and many more.